stockrowAlnylam Pharmaceuticals, Inc. (ALNY) vs BridgeBio Pharma, Inc. (BBIO)
- Alnylam Pharmaceuticals, Inc. ALNY 156.74 +0.05%
- BridgeBio Pharma, Inc. BBIO 75.31 +1.40%
Alnylam Pharmaceuticals, Inc. and BridgeBio Pharma, Inc. are both Biotechnology companies. Alnylam Pharmaceuticals, Inc. is the larger, with a market value of $21.0B against $14.5B — 1.4× the size. BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Alnylam Pharmaceuticals, Inc. trades at 7.9×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 167.3% against 56.2%. Alnylam Pharmaceuticals, Inc. has the higher net margin (52.9% vs −62.6%) and the higher return on invested capital (59.4% vs 0.00%). Across the 17 metrics below, Alnylam Pharmaceuticals, Inc. leads on 13 and BridgeBio Pharma, Inc. on 4.
Valuation
Profitability
| Metric | ALNY | BBIO | Biotechnology median |
|---|---|---|---|
| Gross margin | 77.28% | 94.34% | 65.16% |
| Operating margin | 19.50% | (38.52%) | 0.00% |
| Net margin | 52.85% | (62.62%) | 0.00% |
| Free cash flow margin | 16.08% | (39.11%) | 0.00% |
| Return on equity | 138.07% | 26.22% | (50.12%) |
| Return on assets | 41.25% | (37.48%) | (45.60%) |
| Return on invested capital | 59.37% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack